The commercial environment for biopharmaceutical businesses is becoming more complex and dangerous, and they must have significant knowledge in innovative approaches to portfolio development and decision-making.

Through tactical experience drawn from our larger network of companies, including CRO, CSO, and Communications, our Portfolio Strategy consulting helps customers set direction and make informed decisions about disease areas, innovation, and growth. These decisions are based on scientific understanding and business insights that are informed by tactical experience.

By fusing our network of tactical knowledge with consulting firm capabilities, we help customers create practical plans and create possibilities for true growth.

Our HEOR investigations and analyses are centered on the financial effects of cures, illnesses, and conditions, including the direct costs of medical expenses and indirect costs, like those related to lost wages and disabilities.

Our skilled HEOR team assists clients in determining the value of their products by providing a wide range of services, such as portfolio planning, thorough reviews of the economic and outcomes literature, burden/cost of illness studies, analysis of treatment patterns, trial/market simulation modeling, management of economic endpoints in clinical trials, Patient Reported Outcome (PRO) studies, including quality of life and health utility studies, retrospinning, and more.

With extensive thought leadership in launch and commercial strategy and planning, supported by investments in technology, processes, and frameworks, we have demonstrated global and local launch and commercialization success.

Through more than 675 projects over the past five years, we have partnered with each of our customers to help them develop, commercialize, and enhance their products. We do this by utilizing our in-depth knowledge and extensive expertise.

New Product Development

To guide your efforts in product development and brand planning, we assist you in developing deep customer and therapeutic area insights. In order to position brands strategically, we use an analytical approach to market research, patient journey analysis, and segmentation work. All non-promotional and promotional efforts that support effective commercialization are guided by our evidence-based approach.

Market access has never been more difficult and competitive due to more expensive pharmaceuticals receiving regulatory approval and more scrutiny on drug price. In order to assist you in navigating the market access landscape and maximizing access for your brand, our team provides a broad range of solutions and services.
We can assist you in creating and implementing your market access strategy, whether you work for an organization with a track record of blockbuster launches or a start-up with an exciting pipeline. Our diverse teams’ combined knowledge spans the healthcare continuum, and we can offer your organization and brand-specific assistance and services that are always specialized to assist you in overcoming access difficulties unique to your brand.

Biopharmaceutical producers understand the necessity to develop or modify their business strategies as our sector changes. In spite of changing portfolios, less resources, and increasingly demanding needs, our customers must keep making an impact. We provide creative and useful advice by combining tested analysis approaches, business models, and therapeutic knowledge with the strength of our extensive array of commercial and clinical capabilities.
We combine knowledge, tried-and-true methodology, customer research, and viewpoints to produce recommendations for solutions, processes, and business models that can really be put into action. Our teams include skilled commercial and therapeutic area consulting teams, an industry-leading sales organization, a wide range of communications agencies and capabilities, and subject matter specialists with extensive implementation expertise and tools.

Customers need access to global resources to cover all Good Practice guidelines, independent quality management to certify they are in control of their Quality Management System (QMS), and independent quality management to ensure that they are in control (GxPs). We can assist with the creation or renovation of your QMS.
It is beneficial for every product development program to take into account potential risks and problems as early as feasible in the development process. Because of the commitment of our Quality and Compliance team and our understanding of the various cultures and expectations of inspection agencies, we are able to assess and assist you in managing your risk in a professional, competent, and international manner.

You need a CRO partner who can offer the global regulatory skills to assist your product or device, regardless of the stage of clinical development you’re in. Continue reading to find out more about how we can speed up the approval of drugs by assisting with global product regulatory operations throughout the entire life cycle.
Our regional centers of competence in North America, Europe, and Asia-Pacific provide our global expertise in regulatory consulting and submissions services.

We employ highly qualified people to handle the daily operations related to various multi-sponsor program components. To handle everything from program governance and sponsor management, meeting management, documentation management, vendor selection, identification and performance management, change management, budgeting, and financial reporting, we have developed a number of best-in-class tools, processes, and methodologies.

Our goal is to relieve pressure on your teams. For sponsors to make informed decisions and maintain forward progress, we deliver the pertinent information in timely, palatable formats. For the purpose of offering multi-sponsor engagements program management services, we have created and improved a best-in-class architecture.

In order to consistently improve their operational models, biopharma companies must be flexible and forward-thinking in the clinical development and regulatory environments of today. Our R&D Advisory Group assists biopharma firms of all sizes in concentrating on creating, planning, and implementing significant organizational changes that cater to their particular needs. It is an essential component of Syneos Health Consulting.

The Syneos Health acquisition of Kinapse, a market-leading consultant with extensive experience in R&D organizational, process, and technology-enabled changes, served as the foundation for our R&D Advisory Group. We combine acknowledged professionals across the whole range of research and development with industry-leading consulting skills. To provide our R&D advice services with deep insights, our delivery teams bring together consulting and practical subject matter expertise. Our all-encompassing strategy includes more than just one asset.